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ABSTRACT
Myotonic dystrophy type 1 (DM1) is an autosomal
dominant neuromuscular disorder associated with
a (CUG)n expansion in the 30-untranslated region of
the DMPK (DM1 protein kinase) gene. Mutant DMPK
mRNAs containing the trinucleotide expansion are
retainedinthenucleusofDM1cellsandformdiscrete
foci. The nuclear sequestration of RNA binding pro-
teins and associated factors binding to the CUG
expansions is believed to be responsible for several
of the splicing defects observed in DM1 patients and
could ultimately be linked to DM1 muscular patho-
genesis. Several RNA binding proteins capable of
co-localizing with the nuclear-retained mutant DMPK
mRNAs have already been identified but none can
account for the nuclear retention of the mutant tran-
scripts.Here,wehaveemployedamodifiedUVcross-
linking assay to isolate proteins bound to mutant
DMPK-derived RNA and have identified hnRNP H as
anabundantcandidate.ThespecificbindingofhnRNP
HrequiresnotonlyaCUGrepeatexpansionbutalsoa
splicing branch point distal to the repeats. Suppres-
sion ofhnRNPHexpressionbyRNAirescuednuclear
retention of RNA with CUG repeat expansions. The
identification of hnRNP H as a factor capable of bind-
ing and possibly modulating nuclear retention
of mutant DMPK mRNA may prove to be an important
link in our understanding of the molecular mechan-
isms that lead to DM1 pathogenesis.
INTRODUCTION
Myotonic dystrophy type 1 (DM1) is an autosomal, domin-
antly inherited neuromuscular disorder with a global incidence
of 1 per 8000 (1). Adult onset DM1 is primarily characterized
by myotonia, muscle wasting and weakness, but also affects a
number of organs and results in cataracts, cardiac conduction
abnormalities, testicular atrophy, male baldness and insulin
resistance (1). The mutation responsible for the disease is
a (CUG)n repeat expansion in the 30-untranslated region
(30-UTR) of the DM protein kinase (DMPK) gene (2–4).
Thisrepeatrangesinsizefrom5to37inthenormalpopulation
to between 50 and 1000 in adult onset cases (1).
Amongst several proposed molecular mechanisms, the
RNA dominant mutational model proposes that triplet repeat
expansion causes a gain-of-function at the RNA level (5,6),
possibly by sequestering essential cellular RNA binding
proteins (7–10). Targeting and destruction of mutant DMPK
mRNA releases these factors thus allowing restoration of
several of the normal myotube functions (11,12). In support
of the gain-of-function model, transgenic mice containing
CUG repeats in an unrelated mRNA display myotonia and
a myopathy phenotype (13). Mice transgenic for the human
DMPK region with expanded CTG repeats display muscular
and brain abnormalities (14). Several features of DM1 patho-
genesis can be explained by aberrant alternative-splicing
defects (15). Misregulation of insulin receptor (IR) (16),
muscle-speciﬁc chloride channel (CLC-1) (17,18) and cardiac
troponin T (cTNT) (19) splicing is linked with common symp-
toms of DM1 such as insulin resistance, skeletal muscle
membrane hyperexcitability characteristic of myotonia and
cardiac conduction defects (16,20).
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doi:10.1093/nar/gki698Several CUG repeat binding proteins have been identiﬁed to
date (9,21–26). CUG-BP1 is one of the ﬁrst CUG binding
proteins identiﬁed. While this protein does not co-localize
with the nuclear foci formed by mutant DMPK transcripts,
it has been shown that expression levels of CUG-BP1 are
increased in DM1 (23,27). Functional analyses indicate that
increased expression of CUG-BP1 could be implicated for
the aberrant regulation of cTNT, IR and CIC-1 by binding
to U/G-rich motifs in introns adjacent to the regulated splice
site (28–30). Muscleblind (MBNL) protein family members
in humans have also been shown to bind to CUG repeats
and can also co-localize with the nuclear foci (10,31–34).
Recently, a muscleblind (MBNL1) knock-out mouse was pro-
duced that displayed muscle, eye and RNA splicing abnormal-
ities that are characteristic of DM1 disease (33). Although
MBNL1 protein depletion in mice helps explain some of
the molecular mechanism involved in DM1, it is reasonable
to hypothesize that there are additional CUG binding factors
which work coordinately with these aforementioned CUG
binding proteins.
To address this possibility, we utilized a modiﬁed RNA/
protein crosslinking assay to search for proteins that bind
DM1-derived CUG repeat containing transcripts. This assay
identiﬁed the heterogeneous nuclear ribonucleprotein H
(hnRNP H) as a novel protein capable of binding RNA
with CUG repeats when a branch point sequence is located
downstream. HnRNP H is best known for its role as an
alternative splicing factor and pre-mRNA cleavage and poly-
adenylation (35–39). Surprisingly, we show that knock-down
of endogenous hnRNP H expression by siRNAs in cells
expressing an EGFP gene fused to CUG repeats leads to
release of nuclear sequestrated transcripts and restoration of
EGFP expression. These results could provide insight into the
mechanisms implicated in the nuclear sequestration of mutant
DMPK transcripts in DM1.
MATERIALS AND METHODS
DNA clones
The DMPK clone containing 100 CUG repeats (pRMK-100)
was digested with SacI and EcoRI restriction endonucleases
and cloned into the pGEM vector and further modiﬁed by
deletion of a SacI/SacII fragment (40). Among several sub-
clones containing a variety of CUG repeats, the clones con-
taining 5, 46 and 85 CUG repeats were selected following
sequence conﬁrmation. (CUG)850 which is the (CUG)85
clone with mutated 30 branch site was created by PCR using
two primers (50-GAACGGGGCTCGAAGCTTCCTT-30 and
50-CTAGACTGGAATTCGGCTTATGGTCACTGATC-30)
and cloned into the pBluescript II SK vector. RNAs were
transcribed in vitro using T7 RNA polymerase on linearized
DNA plasmid templates in a 20 ml reaction. For the generation
of biotinylated RNA, 10% of the UTP in the transcription
reaction was replaced with biotinylated UTP (Roche) in
a 100 ml reaction. RNA produced from the transcription reac-
tion was mixed with four volumes of sterile water and
further puriﬁed using a MicroSpin -G50 column (Amersham
Biosciences, Piscataway, NJ). To create the hnRNP H-EGFP
fusion gene, hnRNP H was ampliﬁed by PCR using
two primers (50-CAGCCATATGCTCGAGTGATG-30 and
50-CTTTGTTAGCAGCCGGATCC-30) and the product
cloned into the XhoI/BamHI sites of the pLEGFP-C1 vector
(Clonetech).
Extract preparation and hnRNH H purification
The total cell extracts of HeLa and DM1 cells were prepared
as follows. Cells (1 · 10
8) were harvested and washed with
buffer D, sequentially mixed with 100 ml of buffer D, and son-
icated for 15 s at 4 C. After 5 min of micro-centrifugation at
4 C, the supernatants were collected and used as total cell
extracts. The HeLa nuclear extract was used for the puriﬁca-
tion of CUG binding proteins. The extract was precipitated
with 30% ammonium sulfate, the supernatant was harvested
following a 10 min centrifugation at 4 C: 300 ml of extract was
incubated with 300 ml of pre-washed Streptavidin M-280
Dynabeads for 30 min at room temperature. The extract was
recovered by microcentrifugation and used for puriﬁcation of
CUG binding proteins. The pre-treated extract was incubated
with 30mgofE.colitRNA for20 minatroomtemperature, and
30 mg of biotinylated CUG RNA was mixed and incubated
for an additional 30 min. The buffer D pre-washed beads were
incubated for 30 min and washed three times again with 1 ml
of buffer D. The bound proteins were eluted by buffer D
containing 200 mM KCl. The eluted proteins were separated
in15%SDS–PAGEgel.The50 kDafragmentwasgel-puriﬁed
and sequenced by mass spectrometry in the protein
microsequencing facility of the City of Hope. Recombinant
hnRNP H protein was puriﬁed as described by others (41).
Immunodepletion of hnRNP H
Anti-hnRNP H antiserum (100 ml) was incubated with 200 ml
of Protein A conjugated Dynabeads at room temperature for
1 h. The beads were washed with 1 ml of PBS 5 times and
incubated with 50 ml of the nuclear extract at 4 C for 1 h. The
mixture was spun for 5 min, and the supernatant was used
as the hnRNP H immuno-depleted extract. The depletion of
hnRNP H was conﬁrmed by western blotting with anti-
hnRNP H antisera. For the reconstituted extract, the 20 ml
of the hnRNP H-depleted extract was mixed with 20 ng of
recombinant hnRNP H protein, and incubated at room tem-
perature for 10 min.
In vitro and in vivo crosslinking assay
A total of 10 ml of extract was mixed with E.coli tRNA
(Sigma) at a ﬁnal concentration of 2 mg/ml and incubated
at room temperature for 10 min. G50 column-puriﬁed labeled
RNA (1 ml) was mixed and incubated at room temperature for
20 min. The reaction mixture was pipetted into a Petri dish
maintained at 4 C on ice water. UV crosslinking was per-
formed using a UV Stratalinker 2400 (Stratagene, San Diego,
CA) 5 cm from the light source for 10 min. The irradiated
samples were digested with 10 mg of RNAse A for 10 min at
37 C and resolved in a 10 or 15% SDS–PAGE gel. For UV
crosslinking in the presence of the anti-hnRNP H antibody,
2 ml of the antisera was mixed with the extract for 10 min prior
to the crosslinking treatment.
For in vivoUV crosslinking, DM1 cells were placed on Petri
plates and irradiated by UV as described above. Extracts were
prepared following sonication and incubated in the presence
of antibody-conjugated Protein A conjugated Dynabeads as
described in the section for the immunodepletion assay.
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Non-denaturing composite gel electrophoresis was performed
as described previously (42). The reaction was mixed with
an equal volume of non-denaturing loading dye containing
bromophenol blue and 50% glycerol.
RNAi assays
For synthesis of the siRNA targeting hnRNP H, two sets of
oligos were designed (AS1, 50-AAGGTGGAGAGGGATTC-
GTGGCCTGTCTC-30; S1, 50-AACCACGAATCCCTCTCC-
ACCCCTGTCTC-30). siRNA was synthesized using the
Silencer siRNA construction kit from Ambion (Austin, TX).
ForsiRNAassays, 293T or DM1 cells that were 30% conﬂuent
were transfected with 100 ng of the EGFP-(CUG)85 reporter
gene and the anti-hnRNP H siRNA or a scrambled siRNA
(IDT, Coralville, IA) in a ﬁnal concentration of 10 nM using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). The suppres-
sion of EGFP expression was tested 24 h later. For suppression
of hnRNP H, the cells were harvested after 72 h followed by
total RNA isolation. For knock-down of hnRNP F, a Dicer
substrate dsRNA (43) (sense, 50-GUUAGGAACAUUUUGA-
GUUACUUGAA-30; and antisense, 50-UUCAAGUAACUC-
AAAUGUUCCUAACAA-30) was transfected into HEK293T
cells at a ﬁnal concentration of 20 nM as described above.
Three days later, cells were harvested and divided into two
aliquots. One aliquot was used to prepare total RNA for north-
ern blot assays and the other for preparation of a total cell
extract. For northern blot analyses, a total of 20 mg of RNA
was loaded in each well of a 1% agarose gel and electro-
phoresed and blotted onto a nylon membrane (Hybond). For
hybridization, a hnRNP F-speciﬁc oligonucleotide (50-AAG-
TAACTCAAATGTTCCTAACAA-30) was used.
Primary human muscle cell cultures
DM1, CDM1 and normal control myoblasts were obtained
from the quadriceps of 15-week-old aborted fetuses. The
DM1 fetus had  750 CUG repeats (veriﬁed by Southern blot
analysis). Skeletal muscle biopsies were approved by Laval
University and the CHUL’s ethical committees. Myoblasts
were grown in MCDB-120 supplemented with 15% heat-
inactivated fetal bovine serum, 5 mg/ml insulin, 0.5 mg/ml
BSA, 10 ng/ml human hrEGF, 0.39 mg/ml dexamethasone,
50 mg/ml streptomycin and 50 mg/ml penicillin. Differenti-
ation was carried out in DMEM supplemented with 10 mg/ml
insulin, 10 mg/ml apo-transferrin, 50 mg/ml streptomycin and
50 mg/ml penicillin.
In situ hybridization
Detection of foci was performed using 10 ng of a Cy3-labeled
(CAG)10 oligo (IDT, Coralville, IA) as described (44). Detec-
tion by immunoﬂuorescence involved using two antibodies
(ﬁrst, anti-hnRNP H and second, anti-rabbit antibody conjug-
ated with FITC) as described previously (45).
RESULTS
UV crosslinking of a mutant DMPK 30-UTR binding
protein
The probes used in the in vitro crosslinking assays consisted of
a partialsequenceof the 30-UTRregion ofthe DMPK gene and
contained either (CUG)5, (CUG)46 or (CUG)85 repeats and a
30 splicing branch site (Figure 1A). The DNA was linearized
and used as template for in vitro transcription. The radio-
actively labeled RNA was incubated in a HeLa cell extract
followed by UV crosslinking. We were unable to detect spe-
ciﬁc crosslinking products when the DMPK RNA with ﬁve
CUG repeats (CUG)5 was used for the assays, despite a pre-
vious report that several proteins bind to the CUG elements
(Figure 1B, Lane 1) (46). In contrast to (CUG)5 RNA, when
the (CUG)46 RNA was used as a probe, we obtained a cross-
link to a 50 kDa protein indicated by ‘*’ (lane 3). Interestingly,
the amount of crosslinking to this protein was increased
using the (CUG)85 RNA probe (lane 2). Additional products
were also observed, with approximate molecular weights of
100 and 200 kDa (indicated by the arrowhead in Figure 1B).
To aid in the puriﬁcation of the crosslinked protein(s), we
tested crosslinking to RNAs containing biotinylated UTP.
The binding patterns of unmodiﬁed and biotinylated RNAs
Figure 1. UV crosslinking of CUG repeat RNAs in HeLa nuclear extracts.
(A) RNA clones used. The fragments of the DMPK gene with 5, 46 or 85 CTG
repeats were cloned and transcribed in vitro with T7 RNA polymerase. Black
bars represent the vector sequence common to all three clones. The 30 branch
siteis underlined.(CUG)850 is theclone with85 repeatsofCUGanda mutated
branchsite.(B)UVcrosslinkingusingHeLanuclearextracts.Lane1,(CUG)5;
lane 2,(CUG)85;lane3,(CUG)46;lane4,biotinylated(CUG)46(underlined);
lane 5, with biotinylated (CUG)85 (underlined). (C) UV crosslinking in DM
extracts. Lanes 1 and 2, HeLa total cell extracts; lanes 3 and 4, total DM1
cell extracts before cell differentiation; lanes 5 and 6, DM1 extracts after
differentiation.
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could be used for puriﬁcation of the bound protein(s)
(lanes 4 and 5).
To further investigate of the potential biological relev-
ance of the 50 kDa protein in DM1, we performed the UV
crosslinking assay using extracts prepared from fetal DM1
myoblasts containing 750 repeats (DM1) (Figure 1C). Extracts
were adjusted to similar concentrations prior to the cross-
linking assays. The 50 kDa protein crosslinked products were
observed with the (CUG)85 probe but not with the (CUG)46
probe when the DM1 cell extract was used (Figure 1C, lanes 3
and 4). We did however observe binding of a 35 kDa protein in
both HeLa and DM1 extracts using the (CUG)46 probe.
Because the 35 kDa protein did not bind to the longer CUG
repeats, it was not investigated further.
HnRNP H can bind and dimerize in the presence of
expanded CUG repeats
To identify the 50 kDa protein, we prepared a nuclear HeLa
cell extract, and the interacting protein was further puriﬁed
from the extract using afﬁnity puriﬁcation with biotinylated
(CUG)85 RNA. The RNA–protein complex was puriﬁed using
streptavidin-conjugated beads and the bound proteins were
washed and eluted in high salt: the 50 kDa protein eluted
in 200 mM salt (Figure 2A). The relative differences in eluted
50 kDa protein from the (CUG)46 versus (CUG)85 RNAs may
reﬂect differences in the binding efﬁciencies to these two
different substrates. The proteins eluted from the biotinylated
CUG substrates were excised from the SDS–PAGE gel, eluted
and micro-sequenced. The sequences we obtained from
three peptides were each derived from hnRNP H (Table 1,
for 50 kDa).
Anti-hnRNP H antibodies (a gift from Drs Black and
Helfman) were used to conﬁrm the identity of the CUG
binding protein (Figure 2B). HeLa cell extracts were treated
with either pre-immune or post-immune antisera. UV cross-
linking assays performed on the extracts treated with post-
immune sera demonstrated loss of the 50 and 100 kDa
bands, and revealed enhanced binding of the 35 kDa protein
(Figure 2B). Seemingly, there is competitive binding of
hnRNP H and the 35 kDa protein for the (CUG)85 RNA,
and to a lesser extent to the (CUG)46 RNA. The speciﬁc
inhibition of 100 kDa complex is suggestive of dimer forma-
tion by hnRNP H on this template.
To investigate this hypothesis, we performed immuno-
precipitations using hnRNP H antiserum-conjugated beads
in HeLa cell extracts UV-crosslinked to the (CUG)85 probe
(Figure 2C). Bands migrating at 50 and 100 kDa were gen-
erated from this crosslinking whereas the 35 kDa protein
was absent, demonstrating the speciﬁcity of the antibody.
The larger 100 kDa product was then puriﬁed and micro-
sequenced. As observed previously with the 50 kDa band,
all of the sequenced peptides are derived from hnRNP H
(Table 1, lower column). To eliminate the possibility of
cross-contamination of the 100 kDa protein with the abundant
50 kDa product, the crosslinking was repeated using HeLa cell
extracts prepared from cells treated with an anti-hnRNP H
siRNA (Figure 2D). If the 100 kDa product is indeed a dimer
ofhnRNPH,thenitsexpressionshouldalsobeknocked-down.
Northern gel analyses of hnRNP H mRNA in cells treated with
the anti-hnRNP H siRNA versus a mock siRNA (scrambled)
showed a signiﬁcant reduction in the amount of hnRNP H
mRNA (Figure 2D, top panel). Extracts were prepared from
the siRNA-transfected cells and tested in the crosslinking
assay (Figure 2D, lower panel). Both the 50 and 100 kDa
products were strongly reduced, demonstrating that the
100 kDa crosslinking product requires hnRNP H. Interest-
ingly, binding of the unidentiﬁed 35 kDa protein was restored
when hnRNP H was depleted from the extracts.
Figure 2. . Purification and identification of the CUG repeat binding protein.
(A) Purification of the binding protein. The eluted proteins from the RNA
affinity column using the (CUG)46 or (CUG)85 RNAs were separated in
a SDS–PAGE gel. (B) UV crosslinking assays in extracts treated with pre-
immune(pre)orhnRNPHanti-sera(post).(C) Thecrosslinkingproductswere
treated with pre-immune sera (pre, lane 2) or anti-hnRNP H (post, lane 3).
(D) The levels of hnRNP H and beta-actin were compared from cells that
were mock-transfected or transfected with anti-hnRNP H siRNAs (top panel).
The siRNA-treated cell extracts were used in UV crosslinking assays (bottom
panel).
Table 1. Peptides identified by mass spectrometry
Sequenced protein Identified hnRNP H peptide sequences
50 kDa STGEAFVQFASQEIAEK
HTGPNSPDTANDGFVR
YGDGGSTFQSTTGHCVHMR
VHIEIGPGR
DLNYCFSGMSDHR
VHIEIGPDGR
100 kDa YVEVFK
DLNYCFSGMSDHR
VHIEIGPDGR
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heterodimer (47). Although our data suggest that hnRNP H
itself may dimerize on the longer repeat template (Table 1,
Figure 2C and D), it is still possible that the 100 kDa complex
is comprised of the two proteins. To test whether or not this
is the case, RNAi was used to reduce the level hnRNP
F. Although the RNA level of hnRNP F was reduced by
80% (Supplementary ﬁgure, left panel), we did not observe
an effect on the relative amount of the 100 kDa product in the
UV crosslinking assay (Supplementary ﬁgure, right panel).
HnRNP H dimerization requires additional
cellular factors
In order to assess the binding requirements of hnRNP H
with the DMPK-derived RNA containing CUG repeats, we
produced a puriﬁed recombinant hnRNP H in bacteria. This
protein was capable of forming the 50 kDa complex in our
crosslinking assays but did not form the 100 kDa complex
(Figure 3A, lanes 3 and 4). These results suggest that the
recombinant protein may lack essential post-translational
modiﬁcations or the dimerization requires one or more nuclear
co-factors.
We next immuno-depleted a HeLa total cell extract of
endogenous hnRNP H. Complex formations were resolved
in a native gel assay (Figure 3B). A western blot analysis
was performed to assess the depletion of endogenous hnRNP
H from the extracts (Figure 3B, bottom panel). When hnRNP
H was depleted from the protein extract, there was a reduction
in the high molecular weight complex (Figure 3B, lane 3).
When the depleted extract was reconstituted with recombinant
hnRNP H, formation of the larger complex was restored
(Figure 3B, lane 5). These results indicate that the recombi-
nant protein is capable of binding to the substrate RNA, but
requires additional cellular factor(s) for the formation of large
complexes. MBNL1 and 2 are CUG repeat binding proteins
that co-localize with the foci that contain mutant DMPK
mRNAs with large CUG repeats (9,10). We next sought to
determine if recombinant MBNL1 could facilitate dimeriza-
tion of hnRNP H. But, as can be seen in Figure 3C, recom-
binant MBNL1 had no effect on hnRNP H binding or
dimerization.
Binding of hnRNP H requires the CUG repeats
and a splicing branch point
Based on previous data (Figures 1B, 1C, 2A and 2B), we
speculated that the binding of hnRNP H to CUG repeats is
proportional to the length of the repeats. The recombinant
form of hnRNP H was incubated with different length
CUG repeats and complexes were resolved in a native gel
(Figure 4A). No binding to the (CUG)5 RNA was observed
(lanes 1 and 3). When the (CUG)46 RNA was used in this
assay, only a small fraction of the protein was gel-shifted
(marked as ‘*’ in lane 6). In contrast, the (CUG)85 RNA
was much more gel-shifted (marked as ‘*’ in lane 9). Similar
patterns of complex formation were observed for each RNA
incubated with total cell extracts (lane 5 versus 8). hnRNP H
binds to CUG repeats in a proportional way, which depends
on the length of the CUG repeats.
The different RNAs used in these assays have CUG repeats
as well as a splicing acceptor site derived from a downstream
sequence of the DMPK coding region (46). To understand
the role of this 30 branch site in the binding reaction, a mutant
(CUG)85 clone containing a mutant form of the branch site
was created (marked as (CUG)850, Figure 1A). Interestingly,
the binding of hnRNP H was abolished when the mutant
branch site containing probe was used (Figure 4B, lanes 4
and 5). When the mutated RNA was used for the binding
assay with the total cell extract, the formation of the large
complex was also reduced (data not shown). Our results indic-
ate that CUG repeats and the splicing branch point of Exon 16
are both necessary for hnRNP H binding to the transcripts.
A
C
B
Figure 3. An additional cellular factor(s) is required for dimer formation of
hnRNP H. (A) Recombinant hnRNP H does not dimerize by itself. A UV
crosslinkingassaywascarriedoutusing(CUG)46or(CUG)85RNAsincubated
intotalHeLacellextracts(lanes1and2)orwithrecombinanthnRNPH(lanes3
and 4). (B) A cellular factor is required for hnRNP H dimerization. Lane 1,
(CUG)85 RNA alone; lane 2, (CUG)85 RNA incubated with total HeLa cell
extract; lane 3, (CUG)85 RNA incubated with a hnRNP H-depleted HeLa cell
extract;lane4, (CUG)85RNAincubatedwith10 ngofrecombinant hnRNPH;
lane 5,(CUG)85RNAwithhnRNP Himmuno-depletedextractto which 10ng
of purified recombinant hnRNP H was added prior to (CUG)85 RNA addition.
To confirm immuno-depletion of hnRNP H, the total amount of hnRNP H was
compared prior to (lane 2, bottom panel) and following (lane 3, bottom panel)
immuno-depletion. (C) Recombinant MBNL1 has no effect on hnRNP
H-mediated complex formation. Lane 1, (CUG)85 RNA alone; lane 2,
(CUG)85 RNA incubated with total cell extract; lane 3, (CUG)85 RNA
incubated with 10 ng of recombinant hnRNP H; lane 4, (CUG)85 RNA
incubated with 100 ng of recombinant MBNL1; lane 5, (CUG)85 RNA incu-
bated with 500 ng of MBNL1; lane 6, (CUG)85 RNA incubated with 10 ng of
hnRNP H and 500 ng of MBNL1.
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We next wanted to ascertain whether endogenous hnRNP H
co-localizes with CUG repeats in patient-derived DM1 cells
expressing mutant DMPK transcripts with 750 CUG repeats.
An in situ hybridization was performed to reveal both the
mutant transcripts (red) and endogenous hnRNP H (green)
(Materials and methods) (Figure 5A). Although there was
some apparent hnRNP H co-localization with the foci,
much of the hnRNP H immunostaining was randomly dis-
persed throughout the cell nucleus. To determine if binding
of hnRNP H to the mutant DMPK transcripts in vivo,aU V
crosslinking assay was carried out on DM1 cells (Figure 5B).
DM1 myoblasts were UV-irradiated to crosslink protein–RNA
interactions and hnRNP H was immuno-puriﬁed using the
anti-hnRNP H antibody. No hnRNP H was immuno-puriﬁed
using the pre-immune sera (Figure 5B, lane 1, bottom panel),
whereas hnRNP H anti-sera precipitated hnRNP H from both
irradiated and non-irradiated cells (Figure 5B, lanes 2 and 3,
bottom panel). A phenol extraction was then performed on
equal volumes of each immuno-puriﬁed sample to isolate
bound RNA. The puriﬁed RNA was separated in a denaturing
gel and hybridized with a radioactively labeled (CAG)10
probe (Figure 5B, top panel). Mutant DMPK mRNA was
detected in UV-irradiated samples that were immuno-
puriﬁed with hnRNP H anti-serum. When the parallel experi-
ment was carried out using normal myoblast cells, no bound
RNA was detected in UV-treated immuno-precipitated sam-
ples (data not presented). These results are consistent with
recent ﬁndings by Thornton and colleagues who demonstrated
that hnRNP H and F co-localize, to a limited extent, with
nuclear foci-containing poly-CUG RNA in DM1 patient brain
neurons (48).
RNAi-mediated knock-down of hnRNP H expression
rescues CUG repeat-containing RNAs from nuclear
retention
It has been previously shown that expression of an EGFP gene
fused to expanded CUG repeats in myoblasts results in a
severe reduction of EGFP expression due to nuclear retention
of the transcripts (49). If hnRNP H is in part responsible for
nuclear retention, one would expect that knocking-down
expression of hnRNP H should restore the EGFP-CUG repeat
reporter gene expression. To test this possibility, 293T cells
were transfected with the EGFP-CUG reporter gene and sev-
eral siRNAs (Figure 6A). Transfection of the EGFP-(CTG)5
reporter plasmid and scrambled siRNA in 293T cells resulted
in strong EGFP expression indicating that transcripts with
only ﬁve CUG repeats are readily exported to the cytoplasm
and translated (Figure 6A, panel 1). In contrast, the reporter
plasmid encoding EGFP-(CTG)85 transfected in the presence
of a scramble or anti-EGFP siRNA resulted in only low labels
of EGFP expression (Figure 6A, panels 2 and 3). However,
EGFP expression was restored when siRNAs directed against
hnRNP H were co-transfected with the EGFP-(CTG)85
(Figure 6A, panel 4).
To insure that the rescue of EGFP expression was a direct
effect of the suppression of hnRNP H, aliquots of each cell
sample were processed to prepare total RNAs. Northern
analysis conﬁrmed downregulation of hnRNP H mRNA by
the speciﬁc siRNAs (Figure 6B). Parallel experiments were
B
A
Figure 5. RNA foci of DM1 cells contain hnRNP H. (A) Co-localization assay
for hnRNP H and RNA foci in DM1 cell. First column, immuno-staining of
endogenous hnRNP H; second column, in situ hybridization with a (CAG)10
probe; third column, superimposed images using a double filter. (B) HnRNP H
interacts with CUG repeats in vivo. DM1 myoblast extracts were crosslinked
by UV irradiation. HnRNP H in the total extract was immuno-purified using
the hnRNP H antibody. HnRNP H-associated RNAs were extracted and
resolved in a denaturing gel, blotted to a nylon membrane and probed with
a
32P-labeled(CAG)10DNA(toppanel).Lane1,extractpreparedfromtheUV-
irradiated cells was treated with pre-immune sera; lane 2, extract from non-
irradiated cells was treated with anti-hnRNP H antibody; lane 3, extract from
irradiated cells treated with anti-hnRNP H antisera. To monitor the immuno-
purification procedure, an aliquot of the treated samples was analyzed by
western blotting (bottom panel).
Figure 4. Binding of hnRNP H to CUG repeats is proportional to the length
of the repeats and requires the 30 splicing branch site of exon 16. (A) lane 1,
(CUG)5RNAonly;lane2,(CUG)5RNAwithtotalcellextract;lane3,(CUG)5
with recombinant hnRNP H; lane 4, (CUG)46RNA only;lane 5,(CUG)46 and
total extract; lane 6, (CUG)46 and recombinant hnRNP H; lane 7, (CUG)85
RNA only; lane 8, (CUG)85 and total extract; lane 9, (CUG)85 and recombi-
nant hnRNP H. (B) Binding requires the 30 branch site. Lane 1, (CUG)85 clone
alone; lane 2, (CUG)85 incubated in the total cell extract; lane 3, the RNA was
incubated in the presence of 10 ng of recombinant hnRNP H; lane 4, (CUG)85
RNA with the mutated 30 branch site; lane 5, the mutant RNA with 10 ng of
recombinant hnRNP H protein.
Nucleic Acids Research, 2005, Vol. 33, No. 12 3871performed using normal myoblasts, but the transfection
efﬁciency was <20% (data not presented). Myoblasts were
co-transfected with theEGFP-(CTG)85reportergene andeach
of the siRNAs (Figure 6C). When the myoblasts were trans-
fected with the EGFP-(CTG)85 reporter gene and an irrelevant
siRNA,thelevelofEGFPexpressionwasverylow(Figure6C,
leftpanel). Incontrast,cellstransfectedwith theanti-hnRNPH
siRNAresulted inrescue ofEGFP expression (Figure 6C,right
panel). These results strongly support a role for hnRNP H in
the nuclear retention of DMPK mutant transcripts.
DISCUSSION
Throughthis work, we have identiﬁeda novel protein involved
in binding mutant DMPK mRNA. HnRNP H is not a CUG
binding protein per se, since it requires both a CUG expan-
sion containing at least 46 repeats and a distal sequence con-
taining a splicing branch point, which produces a rare splicing
isoform harboring Exon 16 of DMPK that does not contain
the CUG repeats (46). Under our experimental conditions, we
did not detect binding of other known CUG binding proteins,
such as the Muscleblind family members or CUG-BP1. Some
of the reasons for this could be the use of HeLa cell extracts in
conditions that did not favor optimum expression of these
proteins, the use of a >10-fold excess of a non-speciﬁc RNA
competitor or simply our protein–RNA crosslinking method.
However, our data show that binding of hnRNP H to mutant
DMPK-derived RNAs is speciﬁc and enhanced by cellular
factors present in cell extracts that have yet to be identiﬁed.
In the presence ofthesefactors,we observed the formationofa
complex migrating  100 kDa in the native gel assays. This
complex is absent from extracts made from cells transfected
with small interfering RNAs directed against hnRNP H
or when the extracts have been depleted of endogenous
hnRNP H. These results suggest the formation of a complex
comprised of the mutant RNA, hnRNP H and unidentiﬁed
docking molecules present in our protein extracts. The forma-
tion of such a large complex in the cell nucleus could be linked
to the DMPK mRNA-containing foci present in DM1 cells.
For several years, mouse models of DM1 have been used to
elucidate factors involved in DM1 muscle pathogenesis. The
ﬁrst model to show the true involvement of a CUG expansion
in DM1 was developed by the Thornton (13) and Gourdon
(14,50) laboratories. These mice either expressed the human
skeletal actin gene fused to CTG repeats or the complete
human DM1 locus. The mice in both these models developed
several of the hallmark clinical symptoms of DM1, such as
myotonia and myopathy. The typical formation of nuclear foci
was also observed in histological sections. What these mice
lacked however was the characteristic muscle weakness and
wasting of DM1 patients suggesting other factors are involved
in the pathogenesis, such as haplo-insufﬁciency of the DMPK
protein, over-expression of CUG-BP1 (30) or reduced expres-
sion of the downstream SIX5 gene in humans (51). Recently,
a mouse knock-out of the gene that encodes the MBLN1
protein which binds CUG repeats (also CCUG repeats typical
ofmyotonic dystrophy type 2)has been made (33).These mice
developed abnormalities in RNA splicing, and eye and muscle
defects typical of DM1. These mouse model combined the
SIX5 and DMPK knock-out mice provide the great majority
of symptoms observed in DM1 ranging from the myotonia
to cataract formation and muscle weakness and wasting.
However, what is missing from these models is the identi-
ﬁcation of the factor responsible for mutant DMPK mRNA
sequestration in the nucleus of DM1 cells. Some reports
have provided evidence that reducing mutant transcript
accumulation could restore some molecular features such as
the proper alternative-splicing of the insulin receptor in DM1
cells in vitro (11,12).
A compelling set of data that links hnRNP H to DM1 patho-
genesis is the RNAi-mediated knock-down of hnRNP H
experiments. Experiments with EGFP RNAs containing
expanded CUGs previously designed by Amack and
Mahadevan (49) showed that these transcripts are retained
in the nucleus as measured by reduced EGFP expression.
Using a similar approach, we showed that EGFP expression
could be restored in cells expressing these mutant RNAs if the
level of endogenous hnRNP H is reduced. We performed
RNAi experiments in differentiated DM1 myoblasts to assess
whether foci number and intensity were reduced in cells
depleted of hnRNP H, but poor transfection levels and the
inability to identify transfected cells did not allow us to
obtain conclusive results with these cells (data not shown).
Figure 6. SuppressionofhnRNPHexpressioncanrescuethenuclearretention
ofRNAwithCUGrepeats.(A)HEK293Tcellsweretransfectedwitheitherthe
eGFP-(CUG)5 (Panel 1) or the eGFP-(CUG)85 (Panel 2) reporter genes alone.
An irrelevant siRNA (Panel 3) or an anti-hnRNP H siRNA (Panel 4) were
co-transfected with the eGFP-(CUG)85 reporter. (B) SiRNA-mediated gene-
specific knock-down of hnRNP H (see panels of Figure 6A for lane identities).
(C) SiRNA-mediated expression knock-down of hnRNP can restore expres-
sion of the eGFP-(CUG)85 reporter gene in primary myoblasts. The left
panelshowstransfectionofmyoblastswithanirrelevantsiRNA,therightpanel
shows expression of the reporter in myoblasts transfected with the anti-hnRNP
H siRNA.
3872 Nucleic Acids Research, 2005, Vol. 33, No. 12The mechanisms that underlie DM1 and DM2 pathogenesis
are proving to be extremely complex and challenging to com-
prehend. The pathological CTG and CCTG expansions
responsible for causing these diseases create a true gain-of-
function that alters cellular metabolism in unpredictable ways,
from splicing defects to altering gene expression. In both these
diseases, RNA and protein nuclear sequestration seem to be
at the root of most these disturbances. Our data suggest that
hnRNP H plays a pivotal role in this process.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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